Alberto Jacobo Cunquero-Tomás
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alberto Jacobo Cunquero-Tomás has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Camps
Hospital General Universitario de Valencia, Valencia, Spain
4 shared publications - Vega Iranzo
Consorci Hospital General Universitari de Valencia, Valencia, Spain
3 shared publications - Begoña Campos Balea
Lucus Augusti University Hospital, Spain
2 shared publications Berta Hernández
2 shared publicationsCarlos Camps
Medical Oncology Department, Hospital General Universitario Valencia, Valencia, Spain
2 shared publications- Enrique Espinosa
Service of Oncology, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study
Background: Chemotherapy schemes have historically shown low efficacy in patients with metastatic melanoma and have been replaced by immunotherapy and targeted therapy. This work aimed to study whether chemotherapy remains an option after progression to immunotherapy in specific contexts. Methods: The GEM1801 registry includes patients with advanced melanoma in Spain. For this substudy, patients with metastatic melanoma who received chemotherapy after immunotherapy were selected. Baseline characteristics and treatment outcomes were analyzed. Results: Of the 1316 patients included, with a median time of 4.8 months (range, 0.0–35.8) from the first immunotherapy, 92 received chemotherapy: 12 after adjuvant immunotherapy (cohort A), 45 subsequently to immunotherapy (cohort B), and 35 after receiving bridge therapies (cohort C). The median age was 66 years (range, 35–94), and 55.4% of the patients were male. Most patients had an Eastern Cooperative Oncology Group (ECOG) status of ≤1 (65.2%), whereas only 21.7% had ECOG 2. Among the patients, 54.3% had elevated lactate dehydrogenase levels. Chemotherapy regimens received were taxane/platinum‐based therapies (47.8%), dimethyl triazeno imidazol carboxamide (DTIC) (26.1%), fotemustine (17.4%), and other alkylating agents such as temozolomide (8.7%). With a median follow‐up of 31.9 months, the objective response rate was 12%, the median progression‐free survival was 3.5 months (95% CI, 2.9–4.8), and the median overall survival was 6.1 months (95% CI, 5.3–9.2). Conclusions: As in previous studies, patients treated with chemotherapy after immunotherapy failure had poor outcomes, similar to those from pre‐immunotherapy era, and should be used when no other options are available.
Open AccessReal‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study
Background: Chemotherapy schemes have historically shown low efficacy in patients with metastatic melanoma and have been replaced by immunotherapy and targeted therapy. This work aimed to study whether chemotherapy remains an option after progression to immunotherapy in specific contexts. Methods: The GEM1801 registry includes patients with advanced melanoma in Spain. For this substudy, patients with metastatic melanoma who received chemotherapy after immunotherapy were selected. Baseline characteristics and treatment outcomes were analyzed. Results: Of the 1316 patients included, with a median time of 4.8 months (range, 0.0–35.8) from the first immunotherapy, 92 received chemotherapy: 12 after adjuvant immunotherapy (cohort A), 45 subsequently to immunotherapy (cohort B), and 35 after receiving bridge therapies (cohort C). The median age was 66 years (range, 35–94), and 55.4% of the patients were male. Most patients had an Eastern Cooperative Oncology Group (ECOG) status of ≤1 (65.2%), whereas only 21.7% had ECOG 2. Among the patients, 54.3% had elevated lactate dehydrogenase levels. Chemotherapy regimens received were taxane/platinum‐based therapies (47.8%), dimethyl triazeno imidazol carboxamide (DTIC) (26.1%), fotemustine (17.4%), and other alkylating agents such as temozolomide (8.7%). With a median follow‐up of 31.9 months, the objective response rate was 12%, the median progression‐free survival was 3.5 months (95% CI, 2.9–4.8), and the median overall survival was 6.1 months (95% CI, 5.3–9.2). Conclusions: As in previous studies, patients treated with chemotherapy after immunotherapy failure had poor outcomes, similar to those from pre‐immunotherapy era, and should be used when no other options are available.
- Open Access
- 16 August 2022
- Published by Wiley in Journal of Nutrition and Metabolism
- Vol. 2022 (1) , 1-8
Relation of Malnutrition and Nosocomical Infections in Cancer Patients in Hospital: An Observational Study
Aim. To investigate the relation between malnutrition and nosocomial infections (NI) in hospitalized cancer patients. Methods. This observational, cross-sectional, noninterventional, descriptive study was conducted in a 500-bed university hospital in Valencia (Spain). Adult cancer patients admitted to the oncology ward were consecutively enrolled regardless of their nutritional status between November 2019 and March 2020. Patients were nutritionally assessed 24 to 48 hours after admission. Body weight, height and BMI, body composition through measurement of bioelectrical impedance analysis (BIA), and muscle strength and functionality using hand grip strength (HGS) were prospectively collected. The diagnosis of malnutrition and sarcopenia was assessed using the Global Leadership Initiative on Malnutrition (GLIM) criteria and the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, respectively. Patients were followed up during their hospital stay or outpatient oncology visits to identify possible NI. Results. A total of 107 patients were included in this study (mean age 66 years; 66.4% were men). The most frequent reason for admission was cancer treatment (19.6%), followed by infections (18.7%) and digestive tract symptoms (18.7%). Overall, 77.5% (83/107) of the patients were malnourished at admission according to the GLIM criteria, while 52.3% (56/107) were sarcopenic. Nosocomial infections (NI) were significantly more frequent in malnourished (52.1%; 25/48) and severely malnourished (42.1%; 8/19) patients, compared with well-nourished patients without malnutrition (25%; 10/40; ). The mean length of hospital stay was 13.9 days, significantly longer in patients with an NI compared to those without infections (18.6 vs. 10.8 days, ). Conclusion. This study evidenced the need to implement a routine protocol for the nutritional assessment and support of cancer patients at risk of malnutrition and sarcopenia to reduce the risk of NI during their hospital stay.
- 16 August 2022
- Published by Wiley in Journal of Nutrition and Metabolism
- Vol. 2022 (1) , 1-8
Open AccessRelation of Malnutrition and Nosocomical Infections in Cancer Patients in Hospital: An Observational Study
Aim. To investigate the relation between malnutrition and nosocomial infections (NI) in hospitalized cancer patients. Methods. This observational, cross-sectional, noninterventional, descriptive study was conducted in a 500-bed university hospital in Valencia (Spain). Adult cancer patients admitted to the oncology ward were consecutively enrolled regardless of their nutritional status between November 2019 and March 2020. Patients were nutritionally assessed 24 to 48 hours after admission. Body weight, height and BMI, body composition through measurement of bioelectrical impedance analysis (BIA), and muscle strength and functionality using hand grip strength (HGS) were prospectively collected. The diagnosis of malnutrition and sarcopenia was assessed using the Global Leadership Initiative on Malnutrition (GLIM) criteria and the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, respectively. Patients were followed up during their hospital stay or outpatient oncology visits to identify possible NI. Results. A total of 107 patients were included in this study (mean age 66 years; 66.4% were men). The most frequent reason for admission was cancer treatment (19.6%), followed by infections (18.7%) and digestive tract symptoms (18.7%). Overall, 77.5% (83/107) of the patients were malnourished at admission according to the GLIM criteria, while 52.3% (56/107) were sarcopenic. Nosocomial infections (NI) were significantly more frequent in malnourished (52.1%; 25/48) and severely malnourished (42.1%; 8/19) patients, compared with well-nourished patients without malnutrition (25%; 10/40; ). The mean length of hospital stay was 13.9 days, significantly longer in patients with an NI compared to those without infections (18.6 vs. 10.8 days, ). Conclusion. This study evidenced the need to implement a routine protocol for the nutritional assessment and support of cancer patients at risk of malnutrition and sarcopenia to reduce the risk of NI during their hospital stay.
- 1 August 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (8) , e1162-e1169
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
PURPOSE: Measuring and tracking quality of care is highly relevant in today's health care. The Quality Oncology Practice Initiative (QOPI) program is a referral for evaluating oncology practices worldwide. Excellence and Quality in Oncology Foundation, a collaboration of oncology experts from major Spanish hospitals involved in cancer treatment, reached an agreement with QOPI to include Spanish hospitals in this program. METHODS: We analyzed the results of the QOPI Core module measures from 19 Spanish hospitals over nine rounds (from fall 2015 to fall 2019). RESULTS: Of the 19 hospitals, 15 completed more than one round; none participated in all nine (two hospitals participated in eight rounds). The highest scores were for pathology report confirming malignancy, documenting a plan of care for moderate or severe pain and chemotherapy dose, and chemotherapy administered to patients with metastatic solid tumor with performance status undocumented. Measures regarding a summary of chemotherapy treatment, tobacco use cessation counseling, and assessment of patient emotional well-being were among the lowest scored measures. Six of the 15 practices that participated repeatedly achieved a better score in their last round compared with their first. Overall, scores of Spanish hospitals improved from 67.79% in fall 2015 to 68.91% in fall 2019. CONCLUSION: To our knowledge, this is the first study to evaluate QOPI scores in Spain. There was high variability in scores, with quality of care improving with repeated participation in some hospitals, but worsening in others. Excellence and Quality in Oncology Foundation will support practices to increase their participation to improve oncology care and implement strategies that address the areas for improvement.
- 1 August 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 17 (8) , e1162-e1169
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
PURPOSE: Measuring and tracking quality of care is highly relevant in today's health care. The Quality Oncology Practice Initiative (QOPI) program is a referral for evaluating oncology practices worldwide. Excellence and Quality in Oncology Foundation, a collaboration of oncology experts from major Spanish hospitals involved in cancer treatment, reached an agreement with QOPI to include Spanish hospitals in this program. METHODS: We analyzed the results of the QOPI Core module measures from 19 Spanish hospitals over nine rounds (from fall 2015 to fall 2019). RESULTS: Of the 19 hospitals, 15 completed more than one round; none participated in all nine (two hospitals participated in eight rounds). The highest scores were for pathology report confirming malignancy, documenting a plan of care for moderate or severe pain and chemotherapy dose, and chemotherapy administered to patients with metastatic solid tumor with performance status undocumented. Measures regarding a summary of chemotherapy treatment, tobacco use cessation counseling, and assessment of patient emotional well-being were among the lowest scored measures. Six of the 15 practices that participated repeatedly achieved a better score in their last round compared with their first. Overall, scores of Spanish hospitals improved from 67.79% in fall 2015 to 68.91% in fall 2019. CONCLUSION: To our knowledge, this is the first study to evaluate QOPI scores in Spain. There was high variability in scores, with quality of care improving with repeated participation in some hospitals, but worsening in others. Excellence and Quality in Oncology Foundation will support practices to increase their participation to improve oncology care and implement strategies that address the areas for improvement.
- 14 August 2020
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (4) , 764-772
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial
Background Our previous phase-3 study (TTCC 2503) failed to show overall survival advantage of 2 induction chemotherapy (IC) regimens followed by standard concurrent chemoradiotherapy (CRT) over CRT alone in patients with unresectable locally advanced head and neck squamous-cell carcinoma (LAHNSCC). This study described the long-term survival of those patients. Materials and methods Long-term follow-up study of patients with untreated LAHNSCC assigned to IC (three cycles), with either docetaxel, cisplatin and 5-fluorouracil (TPF arm) or cisplatin and 5-fluorouracil (PF arm), followed by CRT, or CRT alone, included in the previous TTCC 2503 trial. Results In the intention-to-treat population (n = 439), the median OS times were 25.4 (95% CI, 16.8–34.4), 26.2 (95% CI, 18.2–36.6) and 25.4 months (95% CI, 17.4–36.0) in the TPF-CRT, PF-CRT and CRT arms, respectively (log-rank p = 0.51). In the per-protocol population (n = 355), patients with larynx–hypopharynx primary tumors treated with IC (TPF or PF) followed by CRT had a longer median PFS than those who received CRT alone. Moreover, patients with ECOG 0 treated with IC (TPF or PF) followed by CRT had a better TTF than those with CRT alone. There were no statistically significant differences in terms of OS, PFS or TTF, according to the tumor load or affected nodes. Conclusion After a long follow-up, the TTCC 2503 trial failed to show the benefit of IC-CRT in unresectable LAHNSCC regarding the primary end point. However, fit patients with ECOG 0 and primary larynx–hypopharyngeal tumors may benefit from the use of IC if administered by an experienced team. ClinicalTrials.gov identifier NCT00261703
- 14 August 2020
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (4) , 764-772
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial
Background Our previous phase-3 study (TTCC 2503) failed to show overall survival advantage of 2 induction chemotherapy (IC) regimens followed by standard concurrent chemoradiotherapy (CRT) over CRT alone in patients with unresectable locally advanced head and neck squamous-cell carcinoma (LAHNSCC). This study described the long-term survival of those patients. Materials and methods Long-term follow-up study of patients with untreated LAHNSCC assigned to IC (three cycles), with either docetaxel, cisplatin and 5-fluorouracil (TPF arm) or cisplatin and 5-fluorouracil (PF arm), followed by CRT, or CRT alone, included in the previous TTCC 2503 trial. Results In the intention-to-treat population (n = 439), the median OS times were 25.4 (95% CI, 16.8–34.4), 26.2 (95% CI, 18.2–36.6) and 25.4 months (95% CI, 17.4–36.0) in the TPF-CRT, PF-CRT and CRT arms, respectively (log-rank p = 0.51). In the per-protocol population (n = 355), patients with larynx–hypopharynx primary tumors treated with IC (TPF or PF) followed by CRT had a longer median PFS than those who received CRT alone. Moreover, patients with ECOG 0 treated with IC (TPF or PF) followed by CRT had a better TTF than those with CRT alone. There were no statistically significant differences in terms of OS, PFS or TTF, according to the tumor load or affected nodes. Conclusion After a long follow-up, the TTCC 2503 trial failed to show the benefit of IC-CRT in unresectable LAHNSCC regarding the primary end point. However, fit patients with ECOG 0 and primary larynx–hypopharyngeal tumors may benefit from the use of IC if administered by an experienced team. ClinicalTrials.gov identifier NCT00261703
- 20 February 2020
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 20 (6) , 575-582
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer
Introduction: Among non-small cell lung cancer (NSCLC) patients, there is one molecularly defined subgroup harboring activating mutations in the epidermal growth factor receptor gene (EGFR), which results in constitutive activation of its intrinsic kinase activity. Consistent data have demonstrated that these patients have a better outcome when treated with specific tyrosine-kinase inhibitors (EGFR-TKIs). Therefore, analysis of EGFR mutational status for treatment guidance is mandatory in this context. Areas covered: Herein we review the clinical development and technical features of cobas® EGFR Mutation Test v2 as a companion diagnostic test (CDx) for therapy with EGFR-TKIs, such as gefitinib, in advanced NSCLC. We also discuss the pros and cons of the current version of the CDx and its performance in both tissue and plasma samples. Expert opinion: The RT-PCR based cobas® EGFR Mutation Test v2 is a reliable and rapid solution for EGFR mutational status assessment at the time of diagnosis in advanced NSCLC that allows eligibility of patients for EGFR-TKI treatment. This test determines EGFR mutations with acceptable sensitivity in tissue or plasma samples. Pre-analytical considerations like tumor cell content, tumor burden or location of metastasis should be considered to better interpret results in the clinical contexture.
- 20 February 2020
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 20 (6) , 575-582
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer
Introduction: Among non-small cell lung cancer (NSCLC) patients, there is one molecularly defined subgroup harboring activating mutations in the epidermal growth factor receptor gene (EGFR), which results in constitutive activation of its intrinsic kinase activity. Consistent data have demonstrated that these patients have a better outcome when treated with specific tyrosine-kinase inhibitors (EGFR-TKIs). Therefore, analysis of EGFR mutational status for treatment guidance is mandatory in this context. Areas covered: Herein we review the clinical development and technical features of cobas® EGFR Mutation Test v2 as a companion diagnostic test (CDx) for therapy with EGFR-TKIs, such as gefitinib, in advanced NSCLC. We also discuss the pros and cons of the current version of the CDx and its performance in both tissue and plasma samples. Expert opinion: The RT-PCR based cobas® EGFR Mutation Test v2 is a reliable and rapid solution for EGFR mutational status assessment at the time of diagnosis in advanced NSCLC that allows eligibility of patients for EGFR-TKI treatment. This test determines EGFR mutations with acceptable sensitivity in tissue or plasma samples. Pre-analytical considerations like tumor cell content, tumor burden or location of metastasis should be considered to better interpret results in the clinical contexture.
- 1 July 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (2) , 492-495
Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopausal woman: A case report and review of the literature
Introduction: Glucose 6-phosphate dehydrogenase (G6PD) is a basic antioxidant pathway for erythrocytes, being its deficiency the most common gene mutation worldwide. As breast cancer is one of the most frequent tumors, many of these patients may present with G6PD deficiency prior treatment without notice. Case report: We present the case of a woman deficient for G6PD with the diagnosis of Stage IIIB (cT4d cN1 cM0) HER2-enriched early breast cancer. Management and outcome: The patient underwent neoadjuvance with trastuzumab and anthracycline-free chemotherapy, based on docetaxel (75 mg/m2, 120 mg) and carboplatin (AUC 5, 560 mg). She did not present hemolytic crisis and no blood transfusions were needed. She achieved a good pathologic response and completed one-year adjuvant trastuzumab without incidences. Discussion: Although the role of HER2 and trastuzumab in oxidative stress is not yet completely understood, we suggest that trastuzumab may be a suitable agent for treatment in patients with HER2-enriched breast cancer in a non-oxidative chemotherapy scheme, with acceptable responses and no triggering hemolytic crisis.
- 1 July 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (2) , 492-495
Safe neoadjuvant trastuzumab-based treatment in HER2 + inflammatory early breast cancer in a glucose 6-phosphate dehydrogenase-deficient postmenopausal woman: A case report and review of the literature
Introduction: Glucose 6-phosphate dehydrogenase (G6PD) is a basic antioxidant pathway for erythrocytes, being its deficiency the most common gene mutation worldwide. As breast cancer is one of the most frequent tumors, many of these patients may present with G6PD deficiency prior treatment without notice. Case report: We present the case of a woman deficient for G6PD with the diagnosis of Stage IIIB (cT4d cN1 cM0) HER2-enriched early breast cancer. Management and outcome: The patient underwent neoadjuvance with trastuzumab and anthracycline-free chemotherapy, based on docetaxel (75 mg/m2, 120 mg) and carboplatin (AUC 5, 560 mg). She did not present hemolytic crisis and no blood transfusions were needed. She achieved a good pathologic response and completed one-year adjuvant trastuzumab without incidences. Discussion: Although the role of HER2 and trastuzumab in oxidative stress is not yet completely understood, we suggest that trastuzumab may be a suitable agent for treatment in patients with HER2-enriched breast cancer in a non-oxidative chemotherapy scheme, with acceptable responses and no triggering hemolytic crisis.
- 1 February 2018
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 7 (1) , 11
Sweet syndrome as the leading symptom in the diagnosis of gastric cancer
Sweet syndrome is a neutrophilic infiltration of the papillary dermis, which may be associated with the presence of unknown malignancies, either haematological or solid tumours, in 1 out of 5 cases, being considered then as a paraneoplastic syndrome. We present the case of a male with a locally advanced gastric cancer whose final diagnosis was led by the prior debut of Sweet syndrome not explained by other causes.
- 1 February 2018
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 7 (1) , 11
Sweet syndrome as the leading symptom in the diagnosis of gastric cancer
Sweet syndrome is a neutrophilic infiltration of the papillary dermis, which may be associated with the presence of unknown malignancies, either haematological or solid tumours, in 1 out of 5 cases, being considered then as a paraneoplastic syndrome. We present the case of a male with a locally advanced gastric cancer whose final diagnosis was led by the prior debut of Sweet syndrome not explained by other causes.
- 1 November 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (31_suppl) , 251
Oncologist liaison: Satisfaction and symptoms in cancer long survivors.
251 Background: Each year, the prevalence of cancer long survivors (CLS) increases; defined as a person who after five years of diagnosis and treatment is free from disease. Health problems faced by these patients are different from those in general population. Because of that, our service launched in 2007 the figure of the Oncologist Liaison, which acts as a link, and is responsible for assessing these Patients at Specialty Centers. Methods: 238 questionnaires, answered by CLS, were collected between January 2013 and April 2014. Variables of interest were collected by a 18-item questionnaire, designed to assess the aftermath of treatment, socio-emotional impact and employment impact. To assess the performance, methods of descriptive statistics have been used. Results: 90.6% of CLS believe that Oncologist Liaison improves their quality of life, with a decrease in anxiety in 80% of them. 52% of the patients (124) have residual symptoms, being the most frequent asthenia (27.6%). The most prominent symptoms were neurological, such as insomnia (16.5%), anxiety (17.4%) and depression (12.2%). Musculoskeletal problems included myalgia (29.5%), arthralgia (27.5%) and paresthesias (18.3%). Cancer and its treatment have a great impact in sexuality, affecting the 35% of the patients: 24'6% have sexual appetite loss and 7.5% dyspareunia; 10.5% of the men refer impotence and premature ejaculation 5% of them; 28.5% of the women referred vaginal dryness. Conclusions: First, more than half of our patients presented residual symptoms; reporting 90% of them improvement in quality of life related to surveillance. Second, it is necessary to create in our Medical Oncology Services a professional dedicated to coordinate the scientific and organizational aspects necessary for a good follow-up of CLS.
- 1 November 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (31_suppl) , 251
Oncologist liaison: Satisfaction and symptoms in cancer long survivors.
251 Background: Each year, the prevalence of cancer long survivors (CLS) increases; defined as a person who after five years of diagnosis and treatment is free from disease. Health problems faced by these patients are different from those in general population. Because of that, our service launched in 2007 the figure of the Oncologist Liaison, which acts as a link, and is responsible for assessing these Patients at Specialty Centers. Methods: 238 questionnaires, answered by CLS, were collected between January 2013 and April 2014. Variables of interest were collected by a 18-item questionnaire, designed to assess the aftermath of treatment, socio-emotional impact and employment impact. To assess the performance, methods of descriptive statistics have been used. Results: 90.6% of CLS believe that Oncologist Liaison improves their quality of life, with a decrease in anxiety in 80% of them. 52% of the patients (124) have residual symptoms, being the most frequent asthenia (27.6%). The most prominent symptoms were neurological, such as insomnia (16.5%), anxiety (17.4%) and depression (12.2%). Musculoskeletal problems included myalgia (29.5%), arthralgia (27.5%) and paresthesias (18.3%). Cancer and its treatment have a great impact in sexuality, affecting the 35% of the patients: 24'6% have sexual appetite loss and 7.5% dyspareunia; 10.5% of the men refer impotence and premature ejaculation 5% of them; 28.5% of the women referred vaginal dryness. Conclusions: First, more than half of our patients presented residual symptoms; reporting 90% of them improvement in quality of life related to surveillance. Second, it is necessary to create in our Medical Oncology Services a professional dedicated to coordinate the scientific and organizational aspects necessary for a good follow-up of CLS.